PTI-801 Moving to 14 Day Proof of Concept Study in CF Subjects on Orkambi ® PTI-428 Continues to Enroll 28 Day Proof of Concept Study in CF Subjects on Orkambi ® PTI-808 Investigational New Drug Application Now Active; Phase 1 Study in Healthy Volunteers Initiated CAMBRIDGE, Mass.
CAMBRIDGE, Mass. , July 31, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as cystic fibrosis (CF), today announced that it has appointed
Screening Initiated in Phase 2 Portion of PTI-428 Study, 28-day Dosing Cohort CAMBRIDGE, Mass. , June 29, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein
CAMBRIDGE, Mass. , June 23, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as cystic fibrosis (CF), today announced that the Company has filed
Updates Announced During the 40th European Cystic Fibrosis Society Conference CAMBRIDGE, Mass. , June 07, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein
PTI-801 Receives FDA Fast Track Designation; Phase 1 Study Underway IND Submission for PTI-808 Planned for 2Q17 Phase 1 Study of PTI-428 Updated and Ongoing; Results Expected 2Q17 CAMBRIDGE, Mass. , March 30, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc.
CAMBRIDGE, Mass. , Nov. 10, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as cystic fibrosis, today reported financial results for the third
CAMBRIDGE, Mass. , Oct. 26, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as cystic fibrosis, today announced that the company will hold a
CAMBRIDGE, Mass. , Sept. 28, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as cystic fibrosis (CF), today announced the appointment of
Company to Host Analyst and Investor Event Thursday, Oct. 27 at 8:00 p.m. ET CAMBRIDGE, Mass. , Sept. 22, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein
